Bullish option flow detected in ImmunityBio (IBRX) with 13,057 calls trading, 1.1x expected, and implied vol increasing almost 3 points to 114.39%. Apr-26 10 calls and 3/27 weekly 9.5 calls are the most active options, with total volume in those strikes near 5,600 contracts. The Put/Call Ratio is 0.05. Earnings are expected on May 11th.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio announces approval in Macau for Anktiva
- Mixed options sentiment in ImmunityBio with shares up 3.53%
- Buy Rating on ANKTIVA: NCCN Guideline Expansion, Off‑Label Upside, and DCF‑Backed Risk‑Reward in BCG‑Unresponsive NMIBC
- Expanding ANKTIVA’s NMIBC Opportunity: NCCN Endorsement, FDA Flexibility, and Strengthening Long‑Term Prospects for ImmunityBio
- ImmunityBio announces NCCN Guidelines for Bladder Cancer to include Anktiva